News
European collaboration on relative effectiveness assessments: What is needed to be successful?
The open access article “European collaboration on relative effectiveness assessments: What is needed to be successful?” (Kleijnen S, et al. Health Policy (2015)), sets out
The Joint Assessment on “Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma” available
The Joint Assessment of WP5 Strand A on Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal
EUnetHTA joint rapid assessment on sorafenib (Nexavar®) and its use as a treatment of thyroid carcinoma
The joint rapid assessment of WP5 Strand A evaluates ‘sorafenib for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory
National uptake of EUnetHTA’s outputs
A page dedicated to the national uptake of the EUnetHTA’s outputs is now available. Explanation of the terms “national uptake” and “national adaptation” supported by
The summary of the EMA-EUnetHTA face-to-face meeting on 9 December 2014 is available
Meeting minutes from the EUnetHTA-EMA meeting that took place 9 December 2014 in Diemen, the Netherlands is now available. Find the minutes here. Find all minutes
[CLOSED] Public consultation of the draft methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness”
We are pleased to announce that as of today, 27 February, 2015, the draft methodological guideline “Process of information retrieval for systematic reviews and health
The 3rd pilot rapid assessment on ‘Balloon Eustachian Tuboplasty for the treatment of Eustachian tube dysfunction’ is available
We are pleased to announce that the 3rd pilot rapid assessment of JA2 WP5 Strand B on ‘Balloon Eustachian Tuboplasty for the treatment of Eustachian
Roche Pharma reviews the HTA Core Model® from a pharmaceutical perspective
In a report published in December 2014, Roche Pharma reviews the usefulness of the EUnetHTA Core model® for Roche’s internal HTA assembling, storing and sharing
WP7 SG2 Position paper on how to decide on the appropriate study design for AEG available
WP7 Subgroup 2 is pleased to announce the publication of the Position paper on how to decide on the appropriate study design for primary research
WP7 SG2 Position paper on how to best formulate research recommendations for AEG
This document is one of two WP7 SG2 methodological documents aiming to help HTA authors/systematic reviewers in defining their recommendations for Additional Evidence Generation (AEG).
